By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


R-Tech Ueno 

10F, Yamato Life Insurance Building
1-1-7 Uchisaiwaicho, Chiyoda-ku
Tokyo    100-0011  Japan
Phone: 81-3-3596-8011 Fax: 81-3-3596-8023


Company News
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa 3/9/2015 11:33:12 AM
Sucampo Pharmaceuticals, Inc. (SCMP) To Return All Licenses For Unoprostone Isopropyl To R-Tech Ueno 3/9/2015 7:33:51 AM
R-Tech Ueno Received Orphan Drug Designation For Unoprostone Isopropyl (Development Code:UF-021) For The Treatment Of Retinitis Pigmentosa From MHLW 11/25/2014 8:45:52 AM
R-Tech Ueno: Lawsuit Claiming Infringement Of AMITIZA® Capsules Patents 11/13/2014 11:13:46 AM
R-Tech Ueno: Completion Of A Phase I/II Clinical Study Of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) In The U.S. For The Treatment Of Severe Dry Eye 11/10/2014 9:31:53 AM
R-Tech Ueno: Sucampo Pharmaceuticals, Inc. (SCMP) And Takeda (TKPYY) Enter Into Global Licensing Agreement For AMITIZA® (Lubiprostone) 10/23/2014 11:18:09 AM
R-Tech Ueno: Announcement Of Initiation Of The Phase I Clinical Trial For The Novel VAP-1 Inhibitor RTU-1096 10/20/2014 9:27:54 AM
R-Tech Ueno: Settlement Agreement That Resolves Patent Litigation In U.S. Related To AMITIZA® And Company Receives Additional Paragraph IV Notice 10/10/2014 8:29:50 AM
R-Tech Ueno: Announcement Of Collaborative Research With Keio University For Treatment Of Graft-Versus-Host Disease (GVHD) 3/11/2014 9:11:39 AM
R-Tech Ueno Release: Announcement of the Completion of Stage I and the Start of Enrollment for Stage II of the Phase I/II Clinical Trial of Genetically Recombinant Human Serum Albumin (Code: RU-101) Ophthalmic Solution for the Treatment of Severe Dry Eye in the US 11/8/2013 8:11:05 AM